KSPC released the first issue of DIC Newsletter in October 1999. The eight-page bulletin carries information on the activities of drug information & rationale use of drugs, commonly asked enquiries and invited articles from experts from healthcare—specifically pharmaceutical domain. The bulletin is designed for local use within the pharmacy and medical community. One page in every issue is dedicated to articles in Kannada. The DIC newsletter is a member of International Society of Drug Bulletins (ISDB)Read More
This service is provided free of cost to the doctors, pharmacists, students, patients and the general public
Remdesivir is indicated for adults and pediatric patients (12 years of age or older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization. Remdesivir should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care.
The preliminary analysis of Serious Unexpected Serious Adverse Reaction (SUSARs) from the PvPI database reveals that the following drugs are associated with the risks as given below.